Watch Live

Tweet TWEET

Amorfix and QPS to collaborate on Alzheimer's disease project

TSX: AMF 
TORONTO, Jan. 29, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
the Company will collaborate with QPS Holdings, LLC, a leading global provider 
of discovery and development services for pharmaceutical, biotechnology and 
medical device companies, to further develop and validate its proprietary 
Alzheimer's disease diagnostic EP-AD assay. 
The companies will work together to obtain and analyze cerebral spinal fluid 
(CSF) samples from a variety of Alzheimer's disease patients in various stages 
of disease. Amorfix and QPS will perform the studies necessary to validate and 
ultimately commercialize the EP-AD assay for use as both a biomarker to 
facilitate clinical development of new treatments for AD, and an FDA-approved 
early-stage diagnostic test for AD. 
"We are looking forward to working with QPS to validate our EP-AD assay," said 
Dr. Robert Gundel, Amorfix President and CEO. "Our studies using the EP-AD 
assay demonstrate that the EP-AD assay is able to identify early-stage 
patients with mild cognitive impairment (MCI) with a sensitivity of 94%, 
higher than the sensitivity achieved with other biomarkers used as comparators 
in the same study. AD is one of the most active areas of therapeutic 
development with more than 93 new treatments being evaluated in clinical 
studies. We believe that with QPS, we can bring the EP-AD assay to market 
quickly." 
"To promote successful drug development within this challenging indication, 
QPS aims to explore new biomarkers that will facilitate early diagnosis and 
enable meaningful evaluation of drug efficacy for neurodegenerative 
disorders," said Ben Chien, CEO of QPS. "As a leading neuroscience CRO, we 
will work with our partner to develop a wide panel of new biomarkers for 
experimental and clinical use." 
Amorfix will also continue to provide the EP-AD assay for research use to 
pharmaceutical and biopharmaceutical companies on a fee for service basis. 
About Alzheimer's disease
More than 35 million people worldwide have Alzheimer's disease or some other 
type of dementia. AD is most common, and accounts for an estimated 60-80 
percent of cases. Barring a major medical breakthrough, as the world's 
population ages, cases of dementia are predicted to nearly double every 20 
years. By 2040, the number of cases around the world will have quadrupled to 
approximately 81 million people. A major stumbling block to the development of 
effective therapies is the absence of robust biomarkers for early detection, 
and monitoring during clinical trials. A diagnostic tool that can properly 
identify patients with early AD is needed in order for current therapeutics to 
show effectiveness, and for enrolment of such patients into clinical trials. 
About QPS
QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and 
clinical drug development. We provide quality services in Neuropharmacology, 
DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early Stage & Phase 
II - IV Clinical Research to clients worldwide. Our regional facilities and 
offices are located in the USA, China, Taiwan, Japan, India, Netherlands, 
Austria, Czech Republic, Lithuania, Ukraine, Romania, Poland, Croatia, 
Slovenia, Serbia, Bosnia, Hungary, Israel, France, Spain, Germany and the 
United Kingdom. Business development offices are maintained throughout the US, 
Europe, and Asia. QPS employs more than 1000 professionals at ten sites in 
nine countries on four continents. In concert with its global expansion, the 
company is proud of and strives to maintain a friendly and caring company 
culture at all of its business sites. 
QPS has years of experience in neuroscience, as well as global research 
resources and capabilities including early in vitro work, proprietary animal 
models, focus on CNS-specific DMPK issues such as BBB penetration, 
IND-enabling toxicology and clinical research. QPS provides important 
technologies for Phase I clinical trials, such as continuous CNS sampling, 
PET, MRI and sensitive cognitive testing methods, and is able to apply these 
techniques to highly complex Phase II/III trials, including CSF sampling and 
functional and structural imaging. Global expertise in this field guarantees 
top-level scientific consultation and research services. 
For more information, please visit www.qps.com. 
About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
the EP-AD assay, a cerebrospinal fluid (CSF) screening test for Alzheimer's 
disease (AD) and mild cognitive impairment (MCI), and the A4 assay, an 
ultrasensitive method for detecting the hallmark of AD, aggregated 
beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For 
more information about Amorfix, visit www.amorfix.com. 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. This information release may contain certain 
forward-looking information. Such information involves known and unknown 
risks, uncertainties and other factors that may cause actual results, 
performance or achievements to be materially different from those implied by 
statements herein, and therefore these statements should not be read as 
guarantees of future performance or results. All forward-looking statements 
are based on the Company's current beliefs as well as assumptions made by and 
information currently available to it as well as other factors. Readers are 
cautioned not to place undue reliance on these forward-looking statements, 
which speak only as of the date of this press release. Due to risks and 
uncertainties, including the risks and uncertainties identified by the Company 
in its public securities filings, actual events may differ materially from 
current expectations. The Company disclaims any intention or obligation to 
update or revise any forward-looking statements, whether as a result of new 
information, future events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com  Janet 
Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 
847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com 
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/January2013/29/c9338.html 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC ORDER  
-0- Jan/29/2013 12:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.